type that explicitly targets tumors with specialized functions such as improved specificity . This approach includes specific target antigens that CAR T-cells can recognize. Two targets that have sparked interest are γδ T-cells and PSCA (1,7). γδ T-cells express unique T-cell receptors and functional properties in contrast to other αβ T-cells. γδ causes an immune response against cancers such as liver cancer and solid tumors . Integrating these cells into CAR T-cell therapy can leverage the anti-tumor properties within the T-cells and increase the range of the target antigens. Likewise, PSCA is more valuable in the area of prostate cancer . The combination of γδ T-cells and PSCA in CAR T-cell therapy has shown promising results in pre-clinical studies as they have shown that they enhance the treatment's ability . Despite this, it is essential to realize that many factors must be considered when dealing with these proteins, such as target antigen selection, T-cell modification, and potential adverse health outcomes.